公开(公告)号：EP2753348A4

公开(公告)日：2015-05-27

申请号：EP12830783

申请日：2012-09-05

申请人： HANMI SCIENCE CO LTD ,  BEIJING HANMI PHARMACEUTICAL CO LTD

发明人： JUNG SUNG YOUB ,  WOO YOUNG EUN ,  LIM SE YOUNG ,  CHOI IN YOUNG ,  LEE JAE HO ,  KWON SE CHANG ,  MOON SUNG HWAN ,  LIU JIAWANG

IPC分类号： A61K38/21 ,  A61K39/395 ,  A61K47/30 ,  A61K47/48 ,  A61P35/00

CPC分类号： A61K47/642 ,  A61K9/0019 ,  A61K31/7068 ,  A61K38/212 ,  A61K47/48423 ,  A61K47/60 ,  A61K47/68

摘要： A method for preventing or treating a cancer includes administering an anti-cancer pharmaceutical composition including an interferon alpha or a polymer conjugate thereof. The pharmaceutical composition can be co-administered with anti-cancer agents. The interferon alpha conjugate shows a longer in vivo half-life and a more excellent anti-cancer activity than the conventional interferon alpha, and in particular, its co-administration with an anti-cancer agent such as gemcitabine has synergistic inhibitory effects on cancer cell growth and proliferation so as to exhibit a remarkably excellent anti-cancer activity. Further, the anti-cancer pharmaceutical composition has excellent in vivo half-life and anti-cancer activity to greatly reduce administration frequency. Co-administration of an anti-cancer agent and the interferon alpha conjugate having excellent anti-cancer activity reduces administration dose of anti-cancer agent so as to reduce side effects of anti-cancer agent and increase treatment compliance of patient.

摘要翻译： 一种用于预防或治疗癌症的方法包括抗癌药物组合物的施用包含干扰素α或其聚合物缀合物。 所述药物组合物可以共同给药的抗癌剂。 的干扰素α缀合物显示了在体内半衰期和比常规干扰素α更优异的抗癌活性的时间越长，并且特别地，其共同给予含有抗癌剂：如吉西他滨对癌症细胞的协同抑制效果 的生长和增殖，从而显示出显着优异的抗肿瘤活性。 此外，抗癌药物组合物具有优异的体内半衰期和抗癌活性大大降低给药频率。 抗癌剂和具有优异的抗癌活性的干扰素α缀合物的共施用降低抗癌剂的给药剂量，从而减少抗癌剂的副作用和提高患者的治疗顺应性。

公开(公告)号：EP2838549A4

公开(公告)日：2015-12-23

申请号：EP13757286

申请日：2013-03-08

申请人： HANMI SCIENCE CO LTD

发明人： LIM SE YOUNG ,  PARK SUNG HEE ,  SHIN RYOUNG AE ,  CHOI IN YOUNG ,  KWON SE CHANG

IPC分类号： A61K38/17 ,  A61K38/16 ,  A61K38/26 ,  A61K47/48 ,  A61P1/16

CPC分类号： A61K47/48215 ,  A61K38/26 ,  A61K39/3955 ,  A61K47/60 ,  A61K47/6883 ,  A61K2039/505 ,  C07K14/605 ,  C07K16/18 ,  C07K2317/41 ,  C07K2317/75 ,  C07K2317/94

摘要： The present invention relates to a pharmaceutical composition for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD), including a conjugate prepared by covalently linking an insulinotropic peptide, a non-peptidyl polymer and an immunoglobulin Fc region. The composition of the present invention maintains the in-vivo activity of the peptide at a relatively high level, and remarkably increases the blood half-life, thereby preventing triglyceride accumulation which is a typical feature of non-alcoholic fatty liver disease. Ultimately, it can be desirably employed for the prevention and treatment of non-alcoholic fatty liver disease.

公开(公告)号：EP2797621A4

公开(公告)日：2015-09-02

申请号：EP12861579

申请日：2012-12-28

申请人： HANMI SCIENCE CO LTD

发明人： KIM SEUNG SU ,  LIM SE YOUNG ,  JUNG SUNG YOUB ,  KWON SE CHANG

IPC分类号： A61K38/26 ,  A61K47/30 ,  A61K47/48 ,  A61P1/00

CPC分类号： A61K47/48415 ,  A61K38/26 ,  A61K47/48215 ,  A61K47/48369 ,  A61K47/60 ,  A61K47/68 ,  A61K47/6811

摘要： Provided are a glucagon-like peptide-2 (GLP-2) conjugate containing native GLP-2 or its derivative and an immunoglobulin Fc fragment being covalently linked via a non-peptidyl polymer, wherein the native GLP-2 or its derivative has a thiol group introduced at its C-terminal end, and one end of the non-peptidyl polymer is linked to an amino acid residue of the GLP-2 other than the N-terminal amino group thereof; a method for preparing the GLP-2 conjugate; a pharmaceutical composition comprising the same; and a method for treating or preventing intestinal disease, intestinal injury, or gastrosis by using the same. Since the GLP-2 conjugate of the present invention has a remarkably increased binding affinity to a GLP-2 receptor, it shows a prolonged in vivo half-life and an improved in vivo durability and stability.